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CRV community-acquired respiratory virus
DNA deoxyribonucleic acid
EBV Epstein-Barr virus
EPA Environmental Protection Agency
FDA Food and Drug Administration
G-CSF granulocyte colony-stimulating factor (filgastrim)
GM-CSF granulocyte-macrophage colony-stimulating factor (sargramostim)
GVHD graft-versus-host disease
HCW health-care worker
HEPA filter high-efficiency (>90%) particulate air filter
Hib Haemophilus influenzae  type b
HIV human immunodeficiency virus
HLA human lymphocyte antigen
HSCT hematopoietic stem cell transplant; for this report, includes all blood- and marrow-derived
hematopoietic stem cell transplants
HSV herpes simplex virus





LAF laminar air flow
LD Legionnaires’ disease
LRI lower respiratory infection
MIC minimum inhibitory concentration
MRSA methicillin-resistant Staphylococcus aureus
nvCJD new variant Creutzfeldt-Jakob disease
OI opportunistic infection
PCP Pneumocystis carinii  pneumonia
PCR polymerase chain reaction
PZA/RIF pyrazinamide/rifampin
RNA ribonucleic acid
RSV respiratory syncytial virus
TB Mycobacteria tuberculosis
TMP-SMZ trimethoprim-sulfamethasaxole
TST tuberculin skin test
UCB umbilical cord blood
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